Conference
AZD2171 (Cediranib) is active in first line metastatic renal cell carcinoma (RCC): Interim results of a phase II trial. A trial of the PMH Phase II Consortium
Authors
Sridhar SS; Mackenzie MJ; Hotte SJ; Mukherjee SD; Murray N; Tannock IF; Haider MA; Chen EX; Wang L; Srinivasan R
Volume
6
Pagination
pp. 3337S-3338S
Publisher
AMER ASSOC CANCER RESEARCH
Publication Date
December 1, 2007
Conference proceedings
MOLECULAR CANCER THERAPEUTICS
Issue
12
ISSN
1535-7163